Unilever: Q2 Volume Grew 5.5%, the Strongest Quarter in More Than a Decade, but 47.43 Pounds Leaves No Margin of Safety

The stock trades a transformation, not a static staples franchise. The market’s question is whether portfolio surgery, heavier brand investment and tighter execution have produced a structurally faster business, or whether H1 2026 merely caught a favourable period of comparisons, recovery in previously weak markets and temporary volume acceleration.

The latest evidence favours genuine operating improvement, though it does not yet settle the structural question. H1 underlying sales grew 4.8%, comprising 4.2% volume and 0.6% price. Q2 growth accelerated to 5.8%, with 5.5% volume, which management described as the strongest quarterly volume result in more than a decade. Fifteen of 30 Power Brands grew at double-digit rates in Q2. Beauty & Wellbeing, Personal Care and Home Care all delivered Q2 underlying growth above 5%; Foods was nearly flat. On the back of that, Unilever raised full-year underlying sales-growth guidance to 4–6% and expects approximately 3% volume growth.

The quality of that growth deserves attention. After the inflation-driven stretch in which consumer-goods companies leaned on price increases, Unilever now grows on units sold. H1 volume growth of 4.2% exceeded pricing by seven times. Emerging markets generated 7.0% underlying sales growth and 5.8% volume, with India, Indonesia and Latin America contributing. The developed-market result was weaker at 1.5%, and Foods kept losing momentum, including US share pressure in premium and avocado mayonnaise. So the mix is credible but uneven: sharp brand and market execution in household and personal-care categories is offset by developed-market softness and a food portfolio that has become an obvious candidate for separation.

Margins progressed, with an important caveat. H1 underlying operating margin rose ten basis points to 20.3%, despite gross margin falling 70 basis points to 46.8%. Overhead savings of roughly 70 basis points and better productivity paid for higher input costs and brand investment, which reached 16.1% of turnover. A mature consumer company can lift earnings by cutting overhead, but durable compounding requires gross-margin recovery and sustained demand creation. Management expects only modest full-year margin improvement from the 20.0% achieved in 2025, reflecting cost inflation and planned reinvestment.

Cash generation remains a central strength. H1 free cash flow rose to €1.55 billion from €1.08 billion. For full-year 2025, free cash flow was €5.92 billion and cash conversion was approximately 100%. Continuing operations produced €10.77 billion of operating cash flow before income tax, while net capital expenditure was €1.47 billion. Over five years, cash generation has generally run ahead of accounting net income before tax effects and holds up after tax. Recurring restructuring charges and portfolio costs do mean that published “underlying” earnings should not be accepted without adjustment. In 2025, non-underlying operating items totalled approximately €1.05 billion, including €599 million of restructuring and €288 million related to acquisitions and disposals.

The balance sheet is sound, not conservative. Net debt increased from €23.1 billion at the end of 2025 to €26.0 billion at June 2026, equal to approximately 2.3 times rolling underlying EBITDA. The increase included the €1.5 billion buyback, acquisition activity and seasonal cash requirements. Goodwill and intangible assets totalled about €34.8 billion at the end of 2025, which makes acquisition execution and brand valuation relevant balance-sheet risks. The Foods transaction is intended to return leverage toward approximately two times EBITDA, but the same transaction also authorises about €6 billion of buybacks between 2026 and 2029. Sequencing decides the outcome: debt reduction must occur before, or alongside, shareholder distributions.

Unilever’s historical share-price story explains why investors require proof. The group spent much of the 2010s valued as a defensive emerging-market compounder. Kraft Heinz’s $143 billion approach in 2017 pushed the shares sharply higher and forced management to accelerate margin targets, disposals and shareholder returns. The failed 2018 attempt to simplify the dual-headed structure exposed a governance gap between management and UK shareholders. Legal unification finally arrived in 2020. The 2022 pursuit of GlaxoSmithKline’s consumer-health operation for £50 billion then damaged capital-allocation credibility; Unilever’s shares fell more than 8% when the approach became public and recovered when management abandoned it.

The next turn came through activist pressure, new management and portfolio change. Trian’s Nelson Peltz joined the board in 2022. Hein Schumacher became chief executive in 2023 and initiated the Growth Action Plan, including Power Brand concentration, organisational simplification and the ice-cream separation. Fernando Fernandez replaced him in March 2025 after a short tenure, creating another credibility test. Fernandez has since accelerated the portfolio reset, brand spending and performance culture. Q2 2026 produced the best operating evidence yet that these changes are working, and the shares rose about 7.7% on the results day.

Horizontally, Unilever sits in the middle of the pack. Procter & Gamble is the cleaner model of scaled household and personal-care execution, with narrower strategic focus and a longer record of consistent organic growth. L’Oréal owns the best beauty proposition, higher gross margins and faster category exposure, which justifies a premium multiple. Colgate-Palmolive pairs oral-care dominance with high gross margins and disciplined reinvestment. Reckitt is smaller and more concentrated: high margins, but greater litigation and portfolio risk. What sets Unilever apart is global brands plus unusually deep emerging-market distribution. What has held it back is managerial complexity, with too many brands, categories and local layers diluting investment and accountability.

The post-Foods company should compare more favourably with household and personal-care peers. Unilever says the continuing HPC portfolio produced three-year underlying sales growth of 5.4%, volume growth of about 2.5%, gross margin of 48% and underlying operating margin of 19% on a 2025 pro-forma basis. Those metrics beat the conglomerate’s historical growth record, but gross margin remains well below L’Oréal and Colgate. The remaining business also gives up Foods’ roughly 24% operating margin and some diversification. Portfolio purity should raise the growth multiple only if productivity offsets the lost high-margin earnings.

At £47.43, Unilever trades at approximately 18.0 times 2025 underlying EPS converted into sterling, or 19.9 times the data provider’s trailing reported earnings. Its direct 2025 free-cash-flow yield is about 5.0% using company FCF and current market capitalisation, against 3.9% on the LSE tearsheet’s own normalised methodology. Both P/E and EV/EBITDA now sit above their five-year medians: 19.9 versus 16.6 times for P/E, and 15.2 versus 13.8 times for EV/EBITDA. The shares are no longer priced as an impaired conglomerate. They have not reached L’Oréal-style growth valuation either.

A UK ten-year gilt yield of about 5.06% on 2026-07-31 sharpens the valuation debate. Unilever’s roughly 3.5% dividend yield alone sits below the sovereign yield. Owning the equity requires earnings growth, buybacks and multiple stability to earn an adequate premium. If earnings remain flat for three years and the multiple is unchanged, dividends and modest share-count reduction would probably generate only about 4–5% annually, below the gilt yield before allowing for equity risk.

The central bull case is that volume-led growth has become repeatable because the company is concentrating capital behind stronger brands and faster categories. The central bear case is that cost savings, comparison effects and recovery markets explain too much of the improvement, while the company is simultaneously undertaking another complex separation.

One phrase covers it: a company in transition. The qualitative portrait is “company in transition” rather than “mature cash cow” because the operating perimeter, capital structure and peer identity will all change again by mid-2027. Established brands and cash flow give the transformation a solid base. A history of uneven capital allocation and frequent restructuring stops the new model from being treated as proven after one exceptional quarter.

Vertical history and capital-market narrative

Origins and listing path

Unilever began in industrial logic, not brand aggregation for its own sake. Soap and margarine used many of the same oils and fats. At the start of the twentieth century, rapid growth and unstable raw-material supplies pushed Lever Brothers, Jurgens and Van den Bergh toward plantations, supply integration and cooperation. Lever Brothers had already built an international soap network; Jurgens and Van den Bergh responded to weak margarine economics by pooling profits in 1908. Margarine Unie was formed in 1927, and it agreed to combine with Lever Brothers in September 1929. Unilever formally began operations on 1930-01-01.

The original business solved three related problems. It secured oils and fats, standardised branded products that had previously been sold locally or unbranded, and built distribution capable of taking inexpensive goods to mass households. Lever Brothers’ Sunlight model had already shown how product consistency, packaging and advertising could turn soap into a repeat purchase. Its research laboratory at Port Sunlight, built in 1911, added formulation and manufacturing science. The combination with Margarine Unie brought category breadth and continental European scale.

Procter & Gamble entered the UK in 1930 and became a defining rival. The competitive contest was present from Unilever’s beginning: brand investment, formulation, manufacturing scale and retail distribution mattered more than patent monopolies. That remains true today. The current Power Brand model is a modern attempt to restore the concentration that early consumer-goods economics rewarded.

Unilever does not have a conventional single-company IPO date, price or amount raised. The predecessor companies had public share structures, and the group operated for decades through a dual-headed British-Dutch arrangement. The relevant modern listing event was the 2020 legal unification, not an IPO. On 2020-11-30, Unilever began trading with one market capitalisation, one class of shares and a single global liquidity pool while retaining listings in London, Amsterdam and New York. Unilever PLC issued 1.461 billion shares in the exchange, bringing issued capital to 2.629 billion, but did not raise primary capital.

The structure mattered strategically. The previous NV/PLC arrangement imposed duplicated governance and constrained major portfolio actions. Unification placed the parent in the UK, removed Unilever N.V. and gave the board greater flexibility to demerge Ice Cream and pursue the Foods combination. The failed 2018 proposal to move the headquarters to the Netherlands had shown that structural simplicity without shareholder consent could destroy trust. The 2020 transaction succeeded because it preserved London inclusion and did not alter operating locations.

Development stages

Industrial combination and local autonomy

From 1930 through the post-war decades, Unilever expanded by combining manufacturing, brands and local operating companies. The Second World War separated many subsidiaries from London and Rotterdam, reinforcing a decentralised structure in which country businesses adapted to local tastes and supply conditions. That autonomy was useful in markets where retail structures, income levels and consumer preferences differed sharply. It also created a governance inheritance that later became expensive: local businesses accumulated brands, factories and management layers.

The company pushed beyond soap and margarine into frozen and convenience food. The acquisition of Wall’s had already led to factory-produced branded ice cream, while Birds Eye and Batchelors took the group further into packaged food. The strategy followed distribution adjacency: products could be sold through familiar retail relationships and supported by common advertising and procurement capabilities. Over time, though, the categories required different logistics and economics. Ice cream needed freezer ownership and cold-chain capital. Food brands competed on taste and culinary relevance. Personal care increasingly relied on beauty science and premium claims.

The lasting contribution of this stage was geographic depth. Unilever built operating systems in markets that later became major sources of consumer growth, especially India, Indonesia, Brazil and parts of Africa. Its local roots remain a genuine advantage over newer global entrants. The lasting cost was complexity.

Global portfolio building and conglomerate breadth

From the late twentieth century through the early 2010s, Unilever reshaped itself through acquisitions and disposals while pursuing global category leadership. The group reduced its exposure to industrial and commodity activities and assembled large positions in personal care, foods, refreshments and home care. Brands such as Dove became global platforms, not country products. Emerging-market income growth supported a capital-market narrative of a defensive company with faster structural growth than developed-market staples.

The strategy produced scale, and also mixed-quality revenue. Some businesses had powerful repeat-purchase economics and global innovation platforms. Others were regional, slow growing or structurally lower margin. Acquisitions brought goodwill and intangible assets onto the balance sheet, while decentralisation made brand pruning and cost control harder. Investors tolerated the breadth for as long as emerging markets and pricing delivered growth.

By the mid-2010s, the market began demanding greater margin discipline. Kraft Heinz’s 2017 approach exposed the gap between Unilever’s valuable brands and its operating cost base. The $143 billion offer represented an 18% premium and drove Unilever’s shares about 15% higher before the bidder withdrew. Management subsequently accelerated cost savings, disposals and capital returns. The episode genuinely changed Unilever’s operating agenda, though some of the initial response emphasised margin extraction more than brand reinvestment.

Strategic drift and capital-allocation loss of confidence

The 2018–2022 period revealed the limits of incremental reform. The Dutch unification proposal was withdrawn after opposition from UK shareholders concerned about index eligibility and governance. The successful 2020 unification fixed the legal structure, but operating performance remained inconsistent. Pandemic disruption and commodity inflation then tested pricing, supply chains and household demand.

The proposed acquisition of GSK Consumer Healthcare was the sharpest loss of confidence. Unilever offered £50 billion for a business that eventually became Haleon. Investors saw the move as expensive, distracting and inconsistent with management’s claims that internal execution could improve. Unilever shares fell more than 8% when the approach became known. They recovered when management abandoned the pursuit. The market’s message was blunt: repair the existing brands, do not buy growth at a high price.

This period also changed the shareholder base’s tolerance for complexity. Nelson Peltz’s Trian acquired a stake and Peltz joined the board in 2022. The activist did not obtain control, but his presence strengthened pressure for clearer accountability, fewer priorities and more disciplined capital allocation.

Growth Action Plan and portfolio surgery

Hein Schumacher became chief executive in 2023 and launched a programme centred on faster growth, productivity and Power Brands. The March 2024 decision to separate Ice Cream and reduce approximately 7,500 predominantly office-based roles was the decisive move. The shares rose about 3% on the announcement, reflecting investor support for both focus and lower overhead.

Schumacher’s tenure ended sooner than expected. Fernando Fernandez, previously CFO and a long-time operating executive in Latin America and Beauty & Wellbeing, became CEO on 2025-03-01. Unilever shares fell about 3.4% when the change was announced, partly because repeated leadership changes raised questions about board patience and strategic continuity. The board presented the transition as an acceleration rather than a reversal.

Under Fernandez, the company increased brand-and-marketing investment, sharpened the 30-brand Power Brand set and pushed accountability deeper into business groups. Ice Cream legally separated in December 2025. The Foods transaction followed in March 2026. These are connected decisions: Unilever is moving from a diversified food-and-household portfolio toward an HPC company whose economics depend on beauty, hygiene, laundry and premium wellbeing.

The operating evidence firmed up through 2025 and H1 2026. Underlying operating margin reached 20.0% in 2025, compared with 17.6% in the restated 2023 continuing portfolio. Q2 2026 delivered 5.5% volume growth. The next stage is execution, not announcement: close Foods, manage stranded costs, preserve distribution scale and keep brand growth going after the easiest portfolio changes have been made.

Key nodes and their lasting effects

The 2017 Kraft Heinz approach started as a takeover event and turned into an operating catalyst. The bid was withdrawn quickly, yet it exposed latent margin potential and pushed Unilever toward a more shareholder-conscious agenda. In hindsight, its greatest impact was the change it forced in the burden of proof around costs and portfolio returns, not the temporary price jump.

The 2020 unification was underrated by markets focused on immediate earnings. It did not raise revenue or margin, but it enabled later demergers and combinations that would have been harder under the dual-parent structure. One share class and one capital pool also reduced governance friction.

The 2022 GSK Consumer Health bid was genuinely damaging because it revealed weak capital-allocation instincts at the top of the company. Even though no acquisition occurred, shareholders learned that management had been willing to commit £50 billion while internal growth was weak. That memory still limits how much credit the market gives current transaction plans. Haleon’s subsequent existence offers a visible counterfactual: Unilever avoided a large acquisition but lost credibility in the process.

The Growth Action Plan, including Power Brand concentration and higher marketing, is the most important operating node. Its effect can be tested numerically. Power Brands generated 6.0% H1 2026 growth against 4.8% for the group, and 15 of 30 grew at double-digit rates in Q2. That beats a restructuring target as evidence, because it measures consumer demand. The remaining test is whether the non-Power-Brand tail can be sold, harvested or managed without absorbing disproportionate overhead.

The Ice Cream demerger changed reported comparability. All pre-2025 as-reported histories include the divested business unless explicitly restated. Unilever’s 2025 annual report re-presented 2024 and 2023 continuing operations excluding Ice Cream, and those are the preferred figures here. The transaction distributed 80.15% of TMICC, left Unilever with 19.85% and generated accounting effects that should be excluded from operating trend analysis. The fair value of the distributed interest was €6.75 billion, the retained stake €1.67 billion, and the reported demerger gain €3.37 billion.

The Foods combination represents a second attempt to separate unlike economics. Unilever Foods generated €10.73 billion of 2025 turnover, €2.45 billion of operating profit and €2.55 billion of underlying operating profit. At about 24% underlying margin, it is profitable but slower growing. The combined business is expected to have $20 billion of revenue, 21% pre-synergy operating margin and $600 million of annual cost synergies net of reinvestment. The 13.8-times EBITDA valuation appears reasonable relative to listed food assets, but value depends on McCormick execution and the post-close market value of the shares distributed to Unilever holders.

The transaction also creates temporary cost leakage. Unilever estimates €400–500 million of stranded costs and approximately €500 million of restructuring expenditure between 2027 and 2029. These amounts are material relative to annual cost savings and should be deducted from any simplistic “pure-play premium” argument.

Financial vertical review

The following history uses continuing operations excluding Ice Cream for 2023–2025. H1 2025 comparatives were also re-presented. Earlier five-year cash-conversion observations necessarily use the historical group perimeter and are labelled accordingly.

† Full-year 2025 growth rounded from company disclosures. ‡ Derived from turnover and underlying margin; minor rounding difference may arise.

Sources: Unilever’s 2025 annual report, historical continuing-operations information and H1 2026 announcement.

The revenue pattern shows a shift from price to volume. In 2023, underlying sales growth of 7.7% consisted of only 1.1% volume and 6.5% price, largely a response to commodity inflation. In 2024, volume improved to 3.1% while price fell to 1.2%. The first half of 2026 moved further: 4.2% volume and 0.6% price. Read as a sequence, that suggests the company repaired elasticity after the inflation shock and rebuilt units, instead of leaning on perpetual price increases.

Reported turnover is less informative because currency and disposals are large. H1 2026 turnover rose only 0.5% even though underlying sales grew 4.8%; adverse foreign exchange reduced reported turnover by 4.9 percentage points. A GBP investor bears two currency layers: the business earns extensively in emerging-market and US currencies, reports in EUR and trades in GBP. Sterling appreciation against the euro can reduce translated per-share value even when local operations perform well.

Margin expansion from 17.6% in 2023 to 20.0% in 2025 came from gross-margin recovery, productivity and overhead reduction. In H1 2026, the source changed: gross margin declined to 46.8%, while overhead efficiency preserved underlying operating margin. This is lower-quality margin expansion than simultaneous gross-margin and operating-margin improvement. It remains economically useful because Unilever’s inherited overhead structure was excessive, but a prolonged gap between gross-margin pressure and operating-margin growth would eventually force lower marketing or weaker earnings.

Earnings quality is generally strong. Full-year free cash flow remained between €5.9 billion and €6.4 billion during 2023–2025. Underlying ROIC was about 19% in both 2024 and 2025. Cash conversion was around 100% in 2025. Working capital, supplier terms and the low capital intensity of brand ownership support cash generation. Capital expenditure of €1.47 billion was less than 3% of 2025 turnover.

Accounting adjustments are the main qualification. Reorganisation has become recurring. The group recorded roughly €1.05 billion of non-underlying operating items in 2025, including restructuring, deal costs and impairments. The Foods separation will create further stranded-cost removal and restructuring charges. An investor should treat some adjustment as economically recurring while the portfolio remains in motion. Underlying EPS is useful for operating comparisons but overstates owner earnings if every restructuring programme is treated as exceptional.

The balance sheet can fund the transformation but offers limited room for error. Net debt of €25.96 billion at H1 equalled 2.3 times rolling underlying EBITDA. The company’s model targets approximately two times. The Foods cash proceeds should restore that level, although buybacks and acquisitions compete for the same cash. Goodwill and intangible assets of about €34.8 billion are large relative to invested capital, reflecting the economic importance of acquired brands. A broad impairment would not itself consume cash, but it would signal that acquisition returns had fallen below expectations.

Price and valuation history

Over the past decade, Unilever has moved through four broad capital-market identities.

From 2016 through 2019, it was valued as a defensive emerging-market compounder. The Kraft Heinz bid revealed takeover scarcity value and encouraged investors to price stronger margins. Low interest rates also supported long-duration staples valuations.

From 2020 through early 2022, the identity deteriorated into “complex mature conglomerate.” Pandemic demand was mixed by category, commodity inflation pressured margins and the GSK proposal damaged confidence. The market became less willing to pay for emerging-market exposure without consistent volume growth.

Between 2023 and 2025, the stock became a restructuring and re-rating story. The Growth Action Plan, Power Brand focus, planned Ice Cream demerger and cost reductions raised the odds of better earnings quality. Management turnover held back the pace of the re-rating.

In 2026, price discovery has become event driven. Strong Q2 results produced the best daily rise in about two years, but the Foods transaction, higher bond yields and execution costs prevent a full growth-stock valuation. The stock closed £47.43 on 2026-07-31, 14.4% below its 52-week high of £55.42.

Source: London Stock Exchange/FTSE Russell tearsheet, dated 2026-07-31.

The current multiples are above five-year medians because the market has begun to credit portfolio improvement and volume recovery. The direct 2025 underlying P/E calculation is lower: €3.08 underlying EPS converts to £2.64 at the 2026-07-31 ECB rate, producing 18.0 times. Direct 2025 free cash flow of €5.92 billion converts to £5.07 billion, or a 5.0% yield on the current £102.13 billion equity value. Differences from vendor multiples arise from reported-versus-underlying earnings, trailing periods, treatment of discontinued operations and normalisation.

The valuation centre has shifted for both business and macro reasons. Unilever’s operations are improving, but the UK ten-year yield of approximately 5.06% sits far above the near-zero-rate environment that once justified high staples multiples. A sustained valuation above 20 times earnings now requires dependable mid-single-digit EPS growth, not merely defensiveness.

Business model, moat, industry and cycle

Revenue structure and current perimeter

Unilever’s current reporting perimeter contains four business groups. Ice Cream is excluded from continuing operations. Foods remains consolidated until the McCormick combination closes, which is expected by mid-2027. Any valuation of the current share must include Foods, the future transaction consideration and the residual TMICC holding; any operating assessment of the eventual company should separate them.

Source: Unilever H1 2026 results. Totals may not sum due to rounding.

Beauty & Wellbeing is the strategic growth engine. It contains Hair Care, Skin Care, Prestige Beauty and Wellbeing brands such as Liquid I.V., Nutrafol, Paula’s Choice and Hourglass. Hair Care and premium brands supported Q2 growth of 8.1%. These categories can carry higher gross margins, direct-to-consumer distribution and better product innovation than mass foods. They also carry fashion risk and require continuous marketing.

Personal Care is the most balanced profit engine. Dove, Rexona, Axe and Vaseline combine scale, frequent purchase and category extensions. H1 margin of 22.2% exceeded the company average. Vaseline and Dove can stretch across cleansing, deodorants, moisturising and premium formats, allowing common brand equity to support multiple products.

Home Care is the volume and distribution engine. It delivered 7.6% H1 growth, almost entirely from volume. Brands such as Persil, Omo, Surf, Comfort, Cif and Domestos have wide household penetration. Margin of 15.8% was the lowest among the groups, reflecting input intensity, price sensitivity and exposure to local competitors. Its strategic value is larger than its margin alone because it supports distribution density in emerging markets.

Foods is the current cash-rich laggard. Its 23.3% H1 margin was the highest, but sales grew only 1.2% and Q2 was nearly flat. Hellmann’s, Knorr and Unilever Food Solutions retain valuable positions, yet the portfolio has weaker category growth and less strategic overlap with personal and home care. Combining it with McCormick places those brands in a food-focused company while preserving shareholder exposure.

Geographically, 60% of H1 turnover came from emerging markets and 40% from developed markets. Emerging markets grew 7.0%, with 5.8% volume, compared with 1.5% growth in developed markets. This mix is a source of structural volume growth and currency volatility. India, Indonesia and Latin America are especially important. No single retail customer has the economic concentration seen in enterprise businesses, but large chains and digital platforms have negotiating power in developed markets.

Cost structure and operating leverage

Unilever’s largest variable costs are agricultural and petrochemical ingredients, packaging, outsourced production, logistics, trade promotions and certain sales commissions. Labour in factories is partly variable but difficult to reduce quickly. Brand and marketing investment is discretionary in accounting terms but economically necessary; cutting it can raise near-term profit while weakening future demand.

The fixed or semi-fixed base includes factories, distribution centres, research facilities, information systems, category teams, country management, corporate functions and minimum advertising infrastructure. The organisation’s historical country autonomy created duplicate costs. The productivity programme targets those layers while preserving consumer-facing spending.

Operating leverage is positive but moderate. Gross-margin gains can flow through strongly because distribution, research and management do not rise proportionately with every unit sold. The effect can reverse when commodity costs climb faster than pricing. H1 2026 shows both sides: heavy volume and overhead savings held up operating profit, but gross-margin pressure absorbed much of the benefit.

Capex is modest relative to revenue, yet it is not optional. Manufacturing upgrades, digital systems, packaging changes and productivity projects sustain quality and cost competitiveness. The post-Foods plan indicates that more than half of capex will be directed to productivity initiatives. Management also expects combined spending on brand investment, R&D and capex of about 23% of turnover.

Moat

Unilever has four durable moats.

The first is brand memory linked to routine. Dove, Vaseline, Rexona, Knorr, Hellmann’s, Omo and Lifebuoy are embedded in frequent household behaviour. The economic proof is not awareness alone. Power Brands grew faster than the group and generated 78% of turnover in H1 2026. A brand that cannot hold volume after price increases is a marketing asset, not a moat. Unilever’s shift from price-led growth in 2023 to volume-led growth in 2026 is evidence that several core franchises retained consumer relevance.

The second is emerging-market distribution. Unilever can reach modern retailers, traditional small shops, wholesalers and digital channels in countries where logistics and route-to-market execution are difficult. This density supports lower unit-delivery costs and allows launches to scale across price points. Local competitors can beat Unilever in a category or country, but few can match its breadth across India, Indonesia, Latin America and Africa.

The third is formulation and category learning. Consumer-goods R&D is incremental, not revolutionary, but repeated improvements in deodorant efficacy, detergent concentration, skin-care claims, fragrance, packaging and product format matter. Scale lets Unilever spread research over billions of units and adapt global technologies locally. Procter & Gamble and L’Oréal have the same capability, so this is a barrier to smaller entrants rather than an exclusive advantage over the largest peers.

The fourth is retailer economics. A retailer gains from dependable sell-through, category management, marketing support and a portfolio that fills multiple price points. Unilever can negotiate from scale and offer data across categories. This power is constrained by retailer private labels and the concentration of supermarkets and online platforms.

The moat is weaker in premium beauty, supplements and digitally native wellbeing. Consumer loyalty can form quickly but can also migrate with social-media trends. Acquisitions such as Liquid I.V., Nutrafol and Grüns may create growth, yet acquisition price and customer-acquisition costs matter as much as brand recognition. The prestige portfolio should be read as a promising growth platform, not a proven moat on the level of Dove or Vaseline.

Unilever’s moat is broad distribution reinforced by enduring brands; its historic weakness has been converting that advantage into consistently superior execution.

Management and governance

Fernando Fernandez is a career Unilever executive with more than three decades at the company, including leadership roles in Latin America, Brazil and Beauty & Wellbeing, followed by service as CFO. That operating background fits the current need for brand execution and emerging-market growth. It also means the transformation is being led by an insider who participated in the earlier organisation, so cultural change must be judged by outcomes rather than biography.

CFO Srinivas Phatak is likewise a long-serving insider. He became permanent CFO in September 2025 after acting in the role. Leadership continuity reduces transition risk, though it gives the company less external challenge than a fully refreshed executive team might bring. Nelson Peltz’s presence on the board supplies some counterweight and capital-allocation pressure without creating a controlling shareholder.

Capital allocation has improved since the failed GSK bid. The Ice Cream demerger addressed a real strategic mismatch. The Foods combination values the asset at 13.8 times EBITDA, delivers substantial cash and keeps shareholders exposed to the combined company. The acquisition strategy has narrowed toward smaller premium, US, India and digital-first brands rather than transformational deals. The €1.5 billion 2026 buyback reduced shares by 30.7 million.

The concerns are recurring restructuring, leadership turnover and the possibility that buybacks outrun debt reduction. Management’s post-Foods plan includes about €6 billion of repurchases through 2029 and a roughly 60% dividend payout. Those returns are rational only after separation costs and leverage are funded. Buying shares at a full valuation would add less value than investing in brands or retiring debt.

Unilever has one ordinary share class following the 2020 unification and no controlling family, state shareholder or dual-class voting structure. Its governance discount comes from execution history rather than formal minority-shareholder disenfranchisement. There has been no established accounting fraud case central to the investment thesis. Legal and regulatory exposures instead arise from product claims, competition law, tax, packaging, supply chains and individual brand controversies.

Industry structure, cycle and regulation

Global household and personal-care markets are mature in developed economies and structurally growing in emerging markets. Growth comes from population, household formation, hygiene penetration, premium formats, product efficacy and price/mix. Beauty grows faster than basic foods and household cleaning because consumers trade up, add routines and respond to innovation. L’Oréal estimated global beauty-market growth around 4.9% in H1 2026, indicating that Unilever’s Beauty & Wellbeing growth of 5.9% was modestly above the category, while its Q2 acceleration was substantially stronger.

The profit pool sits where brand differentiation is high and ingredient cost is low relative to selling price: prestige beauty, dermatological skin care, deodorants, concentrated household products and certain condiments. Commodity-like cleaning formats and undifferentiated food face lower margins. Unilever’s portfolio direction follows this map by increasing relative exposure to beauty and personal care while separating cold-chain ice cream and most Foods.

Upstream bargaining power rises when palm oil, petrochemicals, dairy, energy, fragrance ingredients or packaging are scarce. Unilever’s scale supports procurement and hedging but does not eliminate inflation. Downstream power is strongest among large supermarkets and digital platforms. Consumers have low monetary switching costs, making habit and perceived efficacy critical.

Entry barriers vary. Launching a beauty brand online is easy; sustaining repeat purchase, claims compliance and international distribution is harder. So large consumer groups face threats from many small entrants but are rarely displaced by one. The economic risk is cumulative share leakage and rising marketing costs.

Unilever is defensive, but not non-cyclical. Demand for soap, deodorant and detergent is stable, while premium beauty, restaurant foodservice and discretionary formats respond to consumer confidence. The group also carries commodity, foreign-exchange, retailer-inventory and emerging-market cycles. Its strongest down-cycle protection is inexpensive pack sizes and category necessity. Its most fragile variables are premium mix, gross margin and the ability to price without losing units.

Policy exposure includes plastics and packaging regulation, environmental requirements, product-safety rules, advertising claims, chemical restrictions, tax and competition law. Regulation generally raises fixed compliance costs, favouring scale, but can require reformulation and capital expenditure. Climate and geopolitical shocks affect agricultural inputs, energy, shipping and currencies rather than the listing itself. The 2026 outlook explicitly incorporates cost pressures associated with conflict-driven commodity inflation and higher second-half pricing.

Horizontal peers and current fundamentals

Competitive landscape

The relevant competitive set is ample, so a Scenario C comparison is appropriate. Procter & Gamble, L’Oréal, Colgate-Palmolive and Reckitt are the most useful primary references. Nestlé, Haleon and Diageo provide secondary comparisons for branded-staples valuation, portfolio focus and UK capital-market conventions.

P&G is the execution benchmark. It has concentrated category positions, a long record of productivity, heavy innovation spending and global household distribution. Customers buy P&G for trusted performance in categories such as fabric care, grooming and personal care. Its strategic identity is narrower and more consistent than Unilever’s. FY2026 sales rose 3% to $87.0 billion, organic growth was 1%, net earnings were $16.1 billion and operating cash flow was $19.6 billion. It returned more than $15 billion through dividends and buybacks. The weakness is mature-category growth: flat volume and cost pressure constrained the FY2027 outlook.

L’Oréal is the global pure-play beauty compounder. Consumers choose it across mass-market, luxury, professional and dermatological channels, and the company moves research, marketing and acquisitions within one broad category. H1 2026 sales were €23.77 billion, like-for-like growth was 6.5% on an adjusted basis, and operating margin was 21.3%. Its 2025 gross margin of about 74% is structurally higher than Unilever’s because beauty products carry more brand value and less material cost. That quality explains a valuation around 33 times earnings.

Colgate-Palmolive has narrowed into an oral-care company with adjacent personal care, home care and pet nutrition. Toothpaste habit, dentist recommendation and global distribution create a particularly durable franchise. Q2 2026 sales rose 4.9%, organic sales 2.4%, gross margin reached 61.5% and adjusted operating margin 21.4%. Colgate’s narrower portfolio supports consistency, though its current reported P/E is elevated and may reflect GAAP items and market expectations beyond near-term organic growth.

Reckitt became a concentrated health, hygiene and nutrition group with powerful individual brands but greater event risk. Its eleven Powerbrands account for more than 80% of core revenue. H1 2026 core like-for-like sales grew 2.7%, accelerating to 4.2% in Q2; gross margin was 60.9% and adjusted operating margin 24.8%. Reckitt’s narrower brand set and high margins are attractive, but litigation exposure, infant-nutrition uncertainty and portfolio disposals support a lower multiple.

Numeric peer comparison

Financial periods differ by company. Revenue and operating figures remain in each issuer’s reporting currency. Valuation multiples are at or near 2026-07-31.

† Adjusted like-for-like measure. ‡ Approximate from FY2026 filings; accounting definitions differ.

Sources: company results and market-data sources.

Unilever trades below P&G because its execution record is weaker and the portfolio is still changing. The discount has narrowed since the GSK episode, since current volume growth now exceeds P&G’s. A sustained post-Foods growth rate above 4% with stable 20% margins could remove much of the discount.

L’Oréal’s premium is justified by category exposure, gross margin and consistency. Unilever should not receive the same multiple merely because Beauty & Wellbeing becomes a larger percentage of the group. Home Care remains material, and Unilever’s beauty operation has yet to match L’Oréal’s global category depth.

Reckitt’s cheaper valuation reflects greater company-specific risk, not inferior current margins. Unilever offers broader geographic and category diversification and a cleaner litigation profile. Reckitt offers stronger gross and operating margins. The relative valuation gap is likely to persist unless Reckitt’s risk clears or Unilever’s growth disappoints.

Colgate represents the strongest narrow moat but a demanding valuation. Unilever’s emerging-market distribution is at least comparable in breadth, yet oral care has more stable habit economics than several Unilever categories.

Ecological niche

Unilever is a global branded-products platform with particular strength in mass household and personal care across emerging markets. Its niche is translating global brand and formulation capabilities into local price points and channels, and it is neither the pure beauty leader nor the cleanest household-products operator.

The company takes profit from local branded competitors, private labels and unbranded consumption. Its own profit pool is most vulnerable to agile digital beauty brands at the premium end and low-cost local detergent or personal-care brands at the mass end. Large retailers can also capture value through private labels and trade terms.

Technological substitution is less threatening than in software or semiconductors. Product and channel fragmentation is the more realistic disruption. Unilever’s position strengthens when regulation raises claims, safety and packaging costs, because it can spread compliance investment across scale. Its position weakens when social-media acquisition allows small brands to grow faster than traditional marketing systems can respond.

Last four quarters and current operating state

The latest four quarters trace an acceleration. Full-year 2025 produced underlying sales growth of 3.5%, a 20.0% underlying operating margin and €5.92 billion of free cash flow. Q1 2026 held up despite cost inflation and geopolitical disruption. Q2 then beat consensus: underlying sales growth of 5.8% against a market expectation around 4.3%, supported by 5.5% volume. The shares rose approximately 7.7% on the print, and management lifted annual guidance.

The strongest acceleration occurred outside Foods. Beauty & Wellbeing rose 8.1% in Q2, Home Care 9.1% and Personal Care 5.9%. Foods grew only 0.2%. Emerging markets outperformed developed markets. The breadth matters: the quarter was not driven by one brand or a single geography. Fifteen Power Brands grew at double-digit rates, and the Power Brand cohort delivered 5.4% volume in H1.

There were one-off and recovery elements. Indonesia had previously suffered execution and channel issues, creating easier comparisons. Developed-market Foods was soft, and US condiments lost share in parts of mayonnaise. Foreign exchange reduced reported turnover. Grüns, acquired in June, added to the wellbeing platform but did not materially drive first-half organic growth.

Profit did not accelerate as fast as volume. Underlying operating profit rose only 0.9%, and underlying EPS rose 2.4%, because currency, input costs and reinvestment absorbed operating gains. Reported diluted EPS fell 2.5%. This gap is central to the next earnings debate: volume leadership must convert into gross margin and per-share cash generation.

Management’s full-year guidance now calls for 4–6% underlying sales growth, approximately 3% volume and modest underlying operating-margin improvement from 20.0%. H2 growth is expected to be 4–5%, with more pricing as cost inflation is passed through. The guidance is achievable after a strong first half, but the price-volume trade-off becomes harder when pricing rises.

What the market is trading

The share price is trading four connected expectations.

First, investors are paying for the possibility that Unilever’s organic-growth centre has shifted from about 3% toward 4–5%. The Q2 volume result is the strongest evidence.

Second, the market expects portfolio focus to improve the earnings mix. Ice Cream is gone, and Foods is due to leave. The continuing company should be more exposed to faster categories, although it also loses Foods’ high margin.

Third, investors expect productivity to fund marketing and margin. H1 overhead savings supported both. The risk is that savings become harder after the obvious corporate layers are removed.

Fourth, shareholders expect transaction proceeds to support debt reduction and buybacks. The approximately €6 billion repurchase programme is meaningful relative to the current £102 billion market value, but it stretches over 2026–2029 and is partly funded by asset separation rather than recurring excess cash.

The real fundamental is volume-led Power Brand growth. The market narrative is that Unilever is becoming a beauty-and-care pure play deserving a higher multiple. The second claim remains incomplete because Home Care will still be large, Foods has not closed and the pro-forma group’s gross margin is below pure beauty peers.

Bull and bear divergence

Bulls point to breadth. H1 volume rose 4.2%, all three continuing HPC groups achieved Q2 sales growth above 5%, emerging markets rose 7% and Power Brands outgrew the company. They argue that concentrated investment is producing share gains rather than a one-brand rebound.

Bulls also point to portfolio arithmetic. The remaining HPC company would have produced 5.4% three-year underlying sales CAGR and approximately 2.5% volume growth, according to management’s pro-forma analysis. Removing slow Foods revenue could raise the group growth rate and reduce conglomerate complexity.

Bears question conversion. H1 gross margin fell 70 basis points, underlying EPS grew only 2.4% and net debt rose to 2.3 times EBITDA. A volume result that does not raise owner earnings proportionately is less valuable than the headline suggests.

Bears also question repeatability. H2 will require more pricing, developed markets remain soft and Foods has visible share issues. A return to price-led growth could reduce volumes, especially in mass-market Home Care.

The most serious bear argument concerns organisational load. Management is integrating Grüns, selling smaller assets, completing TMICC separation work, carving out Foods, designing a new HPC operating model, removing stranded cost and conducting buybacks. Each action is individually rational; the collection creates execution risk.

Valuation, risks and tracking

Historical and peer valuation

At 19.9 times reported trailing earnings and 15.2 times EV/EBITDA, the share is above its five-year median valuation. The five-year period includes the GSK capital-allocation shock, high inflation and transformation uncertainty, so the median may understate a successfully restructured company’s normal multiple. It also includes much lower bond yields, which worked in the opposite direction. Call the current valuation above recent history, and short of an extreme consumer-growth premium.

Relative to P&G, Unilever is modestly cheaper despite much stronger latest volume. That discount is justified by a shorter record of execution and the Foods transaction. Relative to L’Oréal, it is substantially cheaper because its gross margin, category mix and growth quality are lower. Relative to Reckitt, it is more expensive because it carries less litigation and portfolio risk. The cross-section is internally coherent.

A re-rating toward 22 times earnings would require several years of at least 4% organic growth, volume of 2% or more, stable or rising gross margin and clean Foods execution. A return toward 15 times could occur if Q2 proves transitory or if higher gilt yields reset the staples sector.

Cash-flow passthrough and owner earnings

Using the company’s definition, pre-tax operating cash flow exceeded net profit over the last five years. On the historical group perimeter for 2021–2024 and continuing operations for 2025, aggregate pre-tax operating cash flow divided by aggregate net income was approximately 1.6 times. On a stricter after-tax operating-cash-flow basis, the ratio was roughly 1.2 times. The perimeter mismatch prevents false precision, but the conclusion holds: Unilever’s earnings generally convert into cash.

For the comparable 2023–2025 continuing business, annual free cash flow averaged approximately €6.22 billion. The main deductions from operating cash are tax, net interest and net capex. Working-capital movements can make H1 cash flow seasonal, so full-year results are more representative.

Unilever does not disclose maintenance and growth capex separately. A reasonable research assumption is that 65–75% of 2025 net capex was maintenance and regulatory replacement, with 25–35% supporting capacity, productivity and new formats. Applied to €1.47 billion of capex, maintenance capex is approximately €1.0–1.1 billion and growth capex €0.35–0.45 billion. This assumption is supported by the mature manufacturing base and management’s plan to direct more than half of future capex toward productivity, but it is not a company-reported split.

A practical owner-earnings estimate starts with 2025 free cash flow of €5.92 billion and adds back the estimated growth portion of capex, producing about €6.3 billion. Converted at EUR 1 = GBP 0.85573, owner earnings were about £5.4 billion, or approximately £2.50 per current share. The owner-earnings multiple is about 19 times, close to the reported trailing P/E and within 10% of the 18 times underlying-EPS calculation. The difference is well below the prompt’s 30% threshold, so neither accounting earnings nor owner earnings requires exclusive use.

The direct free-cash-flow yield is about 5.0%, and the estimated owner-earnings yield about 5.3%. Those yields sit only slightly above the UK ten-year government yield. The valuation leans on future organic growth and buybacks.

Absolute valuation scenarios

The scenarios use three methods together: owner-earnings yield, normalised P/E and a transaction-adjusted cross-check. They treat the TMICC stake as a finite financial asset and assume the Foods transaction closes on broadly announced terms. Valuation is per current Unilever share in GBP.

The conservative case assumes Q2 volume normalises, H2 pricing reduces elasticity and the post-Foods company receives little re-rating. A value around £44.5 is supported by approximately £2.85 of owner EPS at 15.5 times. This is a mature-staples outcome, not a distress case.

The base case assumes underlying growth around 4–4.5%, at least 2% volume and modest margin improvement. Approximately £3.00 of normalised owner EPS at 17.5–18 times produces value near £52–54. This scenario allows for Foods separation costs and does not award a L’Oréal multiple.

The optimistic case assumes the HPC portfolio sustains approximately 5% growth, Beauty & Wellbeing remains above market and productivity raises margin beyond 21%. £3.20–£3.25 of owner EPS at roughly 20 times supports £64–65. It remains below L’Oréal’s multiple because Unilever’s category mix and gross margin are structurally different.

The scenario values contain uncertainty around the distribution of McCormick shares. Unilever shareholders may receive value partly as securities outside ULVR rather than through the Unilever share price. The ranges capture the economic package attributable to current ownership, but future market quotes may split that value between two listed securities.

This is valuation-scenario analysis within a research framework, not investment advice.

Expectation gap

The current £47.43 price sits above the midpoint of the conservative value and near the lower edge of the base range. The market appears to price underlying growth around 3.5–4%, stable 20% margins and a broadly successful Foods closing. It does not price full HPC-pure-play success.

The largest positive expectation gap would come from sustained volume above 3% while gross margin recovers. That combination would show that investment is driving both share and economics. A second positive gap would be stranded Foods costs below the €400–500 million estimate.

The largest negative gap would be H2 price increases pushing volume below 2%. Another would be Beauty & Wellbeing decelerating toward the market while newer wellbeing acquisitions require higher marketing. A Foods delay beyond mid-2027 would also matter because the valuation narrative rests on timely simplification.

The next scheduled operating update is the Q3 trading statement on 2026-10-28. Investors are likely to focus on volume by group, the pricing response to cost inflation, gross-margin commentary, US condiments, Indonesia and the Foods timetable.

Margin-of-safety recheck

The current price is at a premium to the conservative scenario’s midpoint of approximately £44.5. On that basis, the margin of safety is zero.

The most fragile base-case assumption is that post-Foods owner EPS can reach approximately £3.00 while the margin remains above 20%. If the incremental earnings improvement embedded in that assumption is reduced to 70%, normalised owner EPS would be about £2.90 rather than £3.00. Applying 17 times rather than 17.5–18 times for the weaker delivery produces a value near £49, only modestly above the market price.

If earnings are flat for three years, a 3.5% dividend yield plus approximately 1% annual share-count reduction would produce a total annual return around 4–5%, assuming no multiple compression. That is below the 5.06% UK ten-year gilt yield as of 2026-07-31. There is no margin of safety at this buy price under the flat-earnings case.

This is a good-company, ordinary-price situation, not a bad-price extreme. Waiting has value because £34–36 would offer a discount of 19% to 24% to the conservative value. The opportunity cost is missing continued execution and dividend income if volume growth proves structural.

Margin-of-safety sufficiency verdict: none.

Permanent-loss risks

The first risk is volume normalisation combined with renewed pricing pressure. Probability is medium and impact high. H2 guidance already assumes greater pricing. The observable indicator is underlying volume below 1.5% for two consecutive quarters, especially if pricing exceeds 3%. The transmission path runs from elasticity to lower share, weaker factory utilisation, reduced gross-margin recovery and a valuation reset toward 15 times earnings.

The second risk is portfolio-execution overload. Probability is medium and impact high. Unilever is finishing TMICC separation, carving out Foods, removing stranded cost, integrating acquisitions and changing its operating model. The indicators are a Foods closing beyond mid-2027, stranded costs above €500 million, restructuring cash costs exceeding plan or operational service failures. The loss path would combine delayed proceeds, higher net debt, weaker brand investment and a lower conglomerate multiple.

The third risk is beauty and wellbeing acquisition economics. Probability is medium and impact medium-to-high. The group is buying digital and premium brands to accelerate growth. The observable indicators are slowing organic growth in Prestige and Wellbeing, rising marketing as a percentage of sales without volume response, or impairment of acquired intangibles. The transmission path is lower growth, reduced confidence in the portfolio shift and impairment of the premium multiple.

The fourth risk is gross-margin compression from commodities and currency. Probability is medium-to-high and impact medium. H1 gross margin already fell 70 basis points. Palm oil, chemicals, packaging, energy and freight can rise quickly, while local-currency weakness reduces purchasing power. Gross margin below 46% for two consecutive halves would force a choice between marketing and earnings.

The fifth risk is capital returns funded too aggressively. Probability is low-to-medium and impact high if realised. Net debt stood at 2.3 times EBITDA while the company was conducting buybacks. If net debt remains above 2.5 times after the Foods cash receipt, or if buybacks proceed despite weak FCF, the balance sheet and credit quality could deteriorate. The market would then treat distributions as financial engineering rather than surplus-capital return.

The sixth risk is valuation compression from interest rates. Probability is medium and impact medium. The ten-year gilt yield above 5% competes directly with defensive equities. If organic growth falls toward 2% while long yields remain around 5%, the current 19–20 times multiple would be hard to defend. A move to 14–15 times normalised earnings could reduce the share price by 20–30% even without an earnings decline.

Product safety, plastics regulation, tax disputes, retailer concentration, cyber disruption and geopolitical supply shocks remain relevant, but none currently exceeds the risks above as a likely route to permanent capital loss.

Catalysts and tracking dashboard

Positive catalysts include continued Power Brand volume above 4%, gross-margin recovery in H2, further market-share gains in India and Indonesia, double-digit Beauty & Wellbeing growth, Foods regulatory progress, lower-than-planned stranded costs, disposal of the TMICC stake at an attractive price and buybacks executed below intrinsic value.

Negative catalysts include a Q3 volume slowdown, pricing-induced elasticity, Foods transaction delay, further US condiment share losses, gross margin below 46%, acquisition impairment, leverage above target or a sector-wide multiple reset driven by gilt yields.

Sources: company results, announced timetable and market data.

Volume and Power Brand growth should be read together. Strong volume driven by low-value brands or promotions would be less attractive than Power Brand share gains. Gross margin reveals whether growth is economically productive. Net leverage and transaction timing test capital discipline. The gilt yield sets the opportunity cost and influences the multiple even when operations are stable.

Cross-synthesis and final conclusion

Company fate, industry position and stock pricing

Vertically, what Unilever has proved it can do is build and renew mass consumer franchises across many income levels and distribution systems, not exercise continuous strategic foresight. Its record contains too many brands, repeated restructuring and the failed GSK pursuit. Franchise building is the part that has held up. That capability survived wars, decolonisation, retail consolidation, private-label competition, commodity inflation and digital channels. Dove, Vaseline, Lifebuoy, Rexona, Omo and Knorr remain economically relevant because the company repeatedly adapts formulation, price pack and marketing to local consumers.

The historical success came from a combination of era tailwinds and corporate capability. Population growth, urbanisation and rising incomes expanded demand for packaged household goods. Unilever’s early supply integration and local autonomy allowed it to enter those markets ahead of many rivals. Advertising and retailer scale reinforced the advantage. Management did not create the demographic tailwind, but it built the distribution network that captured it.

Those factors remain, but their relative importance has changed. Emerging-market demand still supports unit growth. Brand and distribution scale still matter. Local autonomy is less valuable when digital marketing, global retail and shared technology reward faster central decisions. The organisation must preserve local consumer knowledge while eliminating duplicated management. The Power Brand and business-group model is intended to make that trade.

Horizontally, Unilever’s advantage over P&G is deeper exposure to several fast-growing emerging markets and a broader beauty-and-wellbeing option. P&G’s advantage is consistency. Against L’Oréal, Unilever offers a lower valuation and greater household necessity; L’Oréal offers superior category economics and beauty focus. Against Colgate, Unilever has greater portfolio breadth but less concentrated habit strength. Against Reckitt, it has more diversification and lower idiosyncratic legal risk but lower margins.

The weakness is partly structural and partly remediable. Lower gross margin than beauty peers is structural because Home Care remains material. Slow decision-making and fragmented brand investment are remediable. Foods complexity is being removed. Whether the remaining company can hold more than 20% operating margin while increasing brand investment is the practical dividing line.

The current valuation rewards some future success. An 18-times underlying P/E and approximately 5% direct FCF yield are not extreme, but the shares no longer offer a clear transformation discount. Current value assumes the Foods transaction completes, volume settles above the company’s older trend and margins do not retreat. It does not assume an L’Oréal-like outcome.

The market may be underestimating the potential persistence of emerging-market volume. H1’s 5.8% emerging-market volume result, combined with improved Indonesia and India execution, could support several years of growth above mature-staples norms. The market may simultaneously be underestimating the cost and distraction of becoming an HPC pure play. The transaction removes Foods revenue but also its high margin, scale and cash generation; €400–500 million of stranded costs must be eliminated before the promised earnings mix appears.

Over the next year, the decisive variables are volume after pricing, gross margin and Foods progress. Over three years, they are the post-separation cost base, Beauty & Wellbeing growth and capital allocation of proceeds. Over five years, the question is whether Unilever can make the HPC portfolio compound at 4–5% organically without frequent large acquisitions.

The company would become a better investment in either of two ways. The first is price: a fall to £34–36 without a deterioration in volume, margin or transaction terms would provide a meaningful margin of safety. The second is evidence: four to six more quarters of at least 2.5% volume, gross-margin recovery and clean Foods execution could justify paying closer to base value.

The research judgment should be overturned negatively if the HPC groups fall below 3% growth, if gross margin remains below 46%, if net debt stays above 2.5 times after transaction proceeds, or if Power Brands cease to outperform. It should be revised positively if the eventual HPC group sustains 5% growth and owner EPS above £3.20 without leveraging the balance sheet.

Core bull reasons

• H1 2026 underlying volume grew 4.2%, and Q2 volume grew 5.5%, the company’s strongest quarter in more than a decade.
• Power Brands generated 78% of turnover, grew 6.0% and outperformed the group, indicating that investment concentration is reaching consumers.
• Beauty & Wellbeing, Personal Care and Home Care all generated Q2 growth above 5%, giving the recovery more breadth than a single-category rebound.
• The pro-forma HPC business had a three-year 5.4% underlying sales CAGR and about 2.5% volume growth, supporting a higher-quality post-Foods mix.
• Free cash flow of €5.92 billion in 2025 and approximately 19% underlying ROIC provide internal funding for brand investment, dividends and controlled buybacks.

Core bear reasons

• H1 gross margin fell 70 basis points and underlying EPS rose only 2.4%, showing that exceptional volume has not yet translated into proportional per-share earnings.
• Foods grew only 0.2% in Q2, and US condiments experienced share pressure, weakening the business before its complex combination with McCormick.
• Net debt rose to €25.96 billion, or 2.3 times EBITDA, while the company continued buybacks and acquisitions.
• The Foods separation carries €400–500 million of stranded cost and roughly €500 million of restructuring expense, which can offset the headline portfolio benefit.
• The stock trades above its five-year median P/E while the UK ten-year gilt yields about 5.06%, leaving little protection if growth returns to the old 2–3% range.

Pre-mortem

A first loss script begins in H2 2026. Conflict-driven input inflation pushes Unilever to raise Home Care and Personal Care prices by 4–5%. Local competitors in India, Indonesia and Latin America hold price or reduce pack sizes. Group volume drops below 1% through 2027, while gross margin remains around 46%. Management protects brand spending, causing underlying operating margin to fall from about 20% to 18.5%. Normalised EPS falls toward £2.40, and the market applies 14 times earnings because ten-year gilt yields remain near 5%. The share price falls to roughly £34 before dividends, around 28% below the research-date price.

A second script centres on transactions. Regulatory or operational problems delay the Foods closing into 2028. Stranded costs reach €700 million, McCormick shares fall as expected synergies are deferred, and Unilever uses cash for buybacks before leverage has normalised. At the same time, a digitally native beauty competitor takes share from two acquired wellbeing brands, forcing higher marketing and an impairment. Owner EPS falls to £2.10–£2.25, and the market applies 11–12 times because management credibility is again impaired. The resulting price of £23–27 would represent a loss of approximately 43–51%.

Final research conclusion

Unilever is becoming a better business, and H1 2026 supplied the strongest evidence yet. Volume growth was broad, Power Brands led the company and the three future HPC groups all expanded. The portfolio strategy also makes economic sense: cold-chain Ice Cream has left, and slow-growing Foods is moving into a food-focused combination at a credible valuation.

The current price already recognises much of that repair. At £47.43, the stock sits above conservative value, near the bottom of the base fair-value range and above its five-year valuation medians. The dividend yield is lower than the UK ten-year gilt yield, so adequate returns require sustained earnings growth. The largest concern is execution density: the company must maintain consumer momentum while completing another separation, removing stranded costs and managing leverage.

The evidence supports ownership at a fair price, but it does not provide a sufficient margin of safety for fresh capital at the research-date close.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: strong
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: medium
• Suitable investor type: long-term growth, dividend and quality-value investors able to tolerate transaction execution risk

【Investment rating】

• Rating: Hold
• One-line thesis: Volume-led Power Brand growth is credible, but current valuation already assumes successful Foods separation and stable margins.
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A purchase trigger is £34–36, provided group volume remains above 2%, underlying operating margin remains at least 20% and the Foods transaction remains on schedule. Waiting sacrifices an annual dividend yield of roughly 3.5% and risks missing a continued re-rating.
• Target holding horizon: 3–5 years
• Expected annualized return: approximately 1% conservative, 8% base and 14% optimistic over three years, including estimated dividends
• Max-loss risk: approximately 45–50% if Foods is delayed, volume falls below 1%, owner EPS declines toward £2.20 and the multiple compresses to 11–12 times
• Reassessment-trigger signals:
  • Group underlying volume below 1.5% for two consecutive quarters
  • Gross margin below 46% or underlying operating margin below 19.5%
  • Foods completion delayed beyond 2027-06-30 or stranded costs above €500 million
  • Net debt above 2.5 times underlying EBITDA after receipt of Foods proceeds
  • Beauty & Wellbeing growth below 3% while marketing intensity rises

【Ideal Buy Price】34–36 GBP

The range is 19–24% below the approximately £44.5 midpoint of the conservative valuation and assumes no deterioration in the operating thresholds above.

• Acceptable hold price: £46–58, centred on the base-case value of approximately £52–54
• Clearly overvalued price: £71–76, beginning more than 10% above the optimistic value of approximately £64–65

【Valuation Range】

• current: 47.43 GBP (close as of 2026-07-31)
• bear (conservative · ideal buy zone): [34, 36]
• base (fair · acceptable hold zone): [46, 58]
• bull (optimistic · above the clearly-overvalued line): [71, 76]

Key data, uncertainties and sources

Key data snapshot

Sources: company results, LSE market data and ECB exchange rates.

Research uncertainties

The first blind spot is post-Foods share arithmetic. The transaction will distribute McCormick equity to Unilever shareholders while Unilever temporarily retains a stake. Tax treatment, final exchange ratios, market prices and jurisdictional mechanics could divide value differently between securities, even if the aggregate economics match the announcement.

The second is maintenance capex. Unilever does not disclose a formal split between maintenance and growth capital. The owner-earnings calculation uses a research estimate of 65–75% maintenance capex; a higher true maintenance requirement would reduce owner earnings.

The third is restated history. The 2023–2025 figures are comparable continuing operations excluding Ice Cream. Earlier five-year cash-conversion figures use the former group perimeter. They are useful for judging cash culture but should not be treated as exact historical data for the post-demerger business.

The fourth is acquired-brand unit economics. Public reporting does not provide complete customer-acquisition cost, repeat-purchase or standalone profitability data for Liquid I.V., Nutrafol, Paula’s Choice, Hourglass and Grüns. Segment growth may conceal wide variation among these assets.

The fifth is consensus forecasting. Publicly accessible analyst-estimate revisions following H1 2026 were incomplete as of the research date. The report leans primarily on company guidance, observed market reaction and independently constructed scenarios rather than a full sell-side consensus model.

Sources

Primary evidence includes Unilever’s H1 2026 results announcement and interim financial information, released 2026-07-28.

The 2025 Annual Report and Accounts supplied continuing-operation financial history, cash flow, return on capital, balance-sheet data, risks and restated comparatives excluding Ice Cream.

Comparable quarterly growth, price and volume figures for 2023–2025 come from Unilever’s historical continuing-operations supplement.

Unilever’s TMICC demerger materials supplied completion, distribution and retained-ownership terms.

Unilever’s Foods and McCormick announcement and presentation supplied transaction value, ownership, cash consideration, synergy, stranded-cost and pro-forma HPC data.

The industrial origins, formation and early competition come from Unilever’s corporate history.

Unilever’s 2020 unification announcement supplied the modern listing path, single share class and capital structure.

London Stock Exchange and FTSE Russell market data supplied the 2026-07-31 price, valuation multiples and historical medians.

The European Central Bank supplied 2026-07-31 EUR, GBP and USD reference exchange rates.

Reuters reporting supplied independent market reaction and analyst context for H1 2026, management changes and major historical events.

P&G, L’Oréal, Colgate-Palmolive and Reckitt filings and results supplied peer operating comparisons.

UK government-bond market data supplied the 2026-07-31 ten-year gilt yield.

Other tickers mentioned

• PG.US — principal global benchmark for household and personal-care execution
• OR.PA — premium beauty benchmark with higher growth and gross margins
• CL.US — oral-care-led consumer-staples peer with concentrated brand habit
• RKT.LSE — UK-listed health and hygiene peer with high margins and greater event risk
• MKC.US — transaction partner combining with Unilever Foods
• HLN.LSE — former GSK consumer-health unit whose attempted acquisition damaged Unilever’s capital-allocation credibility
• DGE.LSE — UK-listed global branded-staples reference for valuation and shareholder-return conventions
• NESN.SW — diversified global food and consumer-staples reference
• MICC.LSE — demerged ice-cream business in which Unilever retains a temporary 19.85% stake
• GSK.LSE — former owner of the consumer-health business pursued by Unilever in 2022
• KHC.US — bidder whose 2017 approach accelerated Unilever’s margin and portfolio agenda

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.